Back to Atlas
APotentially durableStandard research/education caution
CMP-0140
Approved
Transdermal testosterone / AndroGel
Ergogenic / AAS
Raises systemic testosterone with anabolic-androgenic effects
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Transdermal androgen
- Primary mechanism
- Testosterone delivery; AR agonist; A:A ratio 1:1 baseline
- Primary market use
- Hypogonadism / androgen replacement
Pharmacology
- Molecular weight (Da)
- 288.42
- Oral bioavailability
- N/A (transdermal delivery)
- Half-life
- ~10-100 min endogenous; gel maintains 24 h exposure with daily application
- Route tags
- Route-dependent / verify
- Evidence level
- Approved
- Clinical status
- Approved
- Value-for-money score
- 8 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Delivery system rather than new molecule; included as a distinct route/formulation from MESO.